Mitochondria And Metabolic Complications Of HIV
Mitochondria And Metabolic Complications Of HIV
批准号:
7060848
负责人:
PABLO TEBAS
金额:
$16.49万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-05-01 至 2008-10-31
关键词:
HIV infectionsRNAadipose tissueantiAIDS agentblood chemistryblood testscombination chemotherapydisease /disorder etiologydrug adverse effecthuman immunodeficiency virus 1human subjectinsulin sensitivity /resistancelipid metabolismlipodystrophymedical complicationmitochondrial DNAmitochondrial disease /disorderreverse transcriptase inhibitorsstavudine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lipodystrophy associated with HIV infection is very frequent. It affects at least 50% of HIV-1-infected adults receiving antiretroviral therapy (ART) and can be stigmatizing leading to suboptimal adherence to antiretroviral treatment and subsequent clinical and virologic failure. The pathogenesis of this complication of HIV and its treatment is not completely understood. Clinical evidence suggests that specific nucleoside analogue reverse transcriptase inhibitors (particularly d4T and AZT) are associated with peripheral adipose tissue wasting, which may result from mitochondria! toxicity. Mitochondrial toxicity might be also be a contributor to other metabolic complications seen in patients treated for HIV. There has been considerable interest in using mitochondrial DNA measurements in PBMCs as predictors of nucleoside associated toxicity. So far reports have been conflicting because the studies have been underpowered and they lack of longitudinal objective assessments of body composition and other metabolic parameters. The goals of this proposal are:
1. To evaluate longitudinally the peripheral blood mononuclear cell (PBMC) mitochondrial DNA copy number across PBMC specimens obtained in several ACTG studies.
2. To evaluate relationships between longitudinal changes in PBMC mitochondrial DNA copy number and measures of insulin resistance, lipids and fat distribution in three ACTG studies.
3. To evaluate if the changes in mitochondrial DNA measured in PBMC during the first 16-24 weeks of therapy can be used as a predictors of which individuals will develop peripheral lipoatrophy.
4. Exploratory Aim. To evaluate relationships between longitudinal changes in PBMC mitochondrial RNA and RNA copy number and measures of insulin resistance, lipids and fat distribution in three ACTG studies. In order to do this we will use a NASBA based assay to measure the mitochondrial DNA and RNA content in PBMCs, and use 2000 specimens collected longitudinally in 3 large ACTG studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developmental
-
批准号:7684967
-
项目类别:
-
资助金额:$33.24万
-
财政年份:2009
-
负责人:PABLO TEBAS
-
依托单位:
SWITCHING TO A PROTEASE INHIBITOR-CONTAINING, NUCLEOSIDE-SPARING REGIMEN
-
批准号:7953991
-
项目类别:
-
资助金额:$0.51万
-
财政年份:2009
-
负责人:PABLO TEBAS
-
依托单位:
Human Studies of NK-1R anatogonists in HIV-1 (project 4)
-
批准号:7658848
-
项目类别:
-
资助金额:$32.56万
-
财政年份:2008
-
负责人:PABLO TEBAS
-
依托单位:
Core--Developmental Facility
-
批准号:7650387
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2008
-
负责人:PABLO TEBAS
-
依托单位:
Human Studies of NK-1R anatogonists in HIV-1 (project 4)
-
批准号:7516469
-
项目类别:
-
资助金额:$43.24万
-
财政年份:2007
-
负责人:PABLO TEBAS
-
依托单位:
SWITCHING PROTEASE INHIBITOR COMBO ANTIRETROVIRAL THERAPY TO NEVIRAPINE FOR HIV
-
批准号:7355184
-
项目类别:
-
资助金额:$1.39万
-
财政年份:2006
-
负责人:PABLO TEBAS
-
依托单位:
Human Studies of NK-1R anatogonists in HIV-1 (project 4)
-
批准号:6998372
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2005
-
负责人:PABLO TEBAS
-
依托单位:
Mitochondria And Metabolic Complications Of HIV
-
批准号:6947701
-
项目类别:
-
资助金额:$18.35万
-
财政年份:2005
-
负责人:PABLO TEBAS
-
依托单位:
SWITCHING PROTEASE INHIBITOR COMBO ANTIRETROVIRAL THERAPY TO NEVIRAPINE FOR HIV
-
批准号:6977126
-
项目类别:
-
资助金额:$1.6万
-
财政年份:2003
-
负责人:PABLO TEBAS
-
依托单位:
STRATEGIC MANAGEMENT OF ANTIRETROVIRALS IN HIV INFECTION
-
批准号:2828961
-
项目类别:
-
资助金额:$11.14万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
STRATEGIC MANAGEMENT OF ANTIRETROVIRALS IN HIV INFECTION
-
批准号:6168751
-
项目类别:
-
资助金额:$11.4万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
Developmental Core
-
批准号:9925287
-
项目类别:
-
资助金额:$47.93万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
Developmental Core
-
批准号:10212193
-
项目类别:
-
资助金额:$131.05万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
Developmental Core
-
批准号:10463864
-
项目类别:
-
资助金额:$235.71万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
STRATEGIC MANAGEMENT OF ANTIRETROVIRALS IN HIV INFECTION
-
批准号:6372633
-
项目类别:
-
资助金额:$11.65万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
Developmental Core
-
批准号:10656361
-
项目类别:
-
资助金额:$81.58万
-
财政年份:1999
-
负责人:PABLO TEBAS
-
依托单位:
ACTG 328--PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN 2
-
批准号:6263483
-
项目类别:
-
资助金额:$2.44万
-
财政年份:1998
-
负责人:PABLO TEBAS
-
依托单位:
AIDS CLINICAL TRIALS UNIT
-
批准号:6701318
-
项目类别:
-
资助金额:$144.83万
-
财政年份:1992
-
负责人:PABLO TEBAS
-
依托单位:
AIDS CLINICAL TRIALS UNIT
-
批准号:7150501
-
项目类别:
-
资助金额:$145.7万
-
财政年份:1992
-
负责人:PABLO TEBAS
-
依托单位:
AIDS CLINICAL TRIALS UNIT
-
批准号:6607259
-
项目类别:
-
资助金额:$164.73万
-
财政年份:1992
-
负责人:PABLO TEBAS
-
依托单位:
国内基金
海外基金
登录
查看更多内容
免标记CRISPR-RNA适配体与门逻辑分子诊断新方法研究
-
批准号:2026JJ50010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:应站明
-
依托单位:
RNA m6A修饰通过调控FDX1介导的铜死亡参与补阳还五汤抗脑缺血再灌注损伤作用机制的研究
-
批准号:2026JJ81091
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:刘亮
-
依托单位:
基于合成生物标志物的超多重RNA数字化检测平台用于肿瘤精准诊断和分期评估
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:程子译
-
依托单位:
RNA 结合蛋白HuR与VEGF-D联合调控舌鳞癌侵袭及转移机制的研究
-
批准号:2026JJ80684
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:龚攀
-
依托单位:
Dead-box解旋酶DDX23通过调控RNA高级结构促进肝癌细胞恶性生物学行为的分子机制研究
-
批准号:JCZRLH202600588
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于基因编辑技术解析丹酚酸B靶向SAMHD1调控心肌线粒体RNA稳态干预心衰的分子机制研究
-
批准号:JCZRLH202601084
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于异质人群多源数据识别单细胞 RNA数量性状风险位点的统计学方法研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:蔡铭轩
-
依托单位:
uN2CpolyG蛋白经ALYREF蛋白介导RNA转运异常在神经元核内包涵体病发病中的作用及机制研究
-
批准号:2026JJ60587
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张思哲
-
依托单位:
病毒非编码RNA多样性图谱构建及其生物发生与致病机制研究
-
批准号:2026JJ60389
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:傅萍
-
依托单位:
核糖核酸酶RNase E与其抑制因子RebA通过液-液相分离调控蓝藻RNA代谢的分子机制
-
批准号:JCZRQNB202600879
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: